{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:56:03Z","timestamp":1790488563759,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EU FP7","award":["305266 \u2018MIAMI\u2019"],"award-info":[{"award-number":["305266 \u2018MIAMI\u2019"]}]},{"DOI":"10.13039\/100001063","name":"Crohn\u2019s and Colitis Foundation of America","doi-asserted-by":"crossref","award":["CCFA ref. no. 1911"],"award-info":[{"award-number":["CCFA ref. no. 1911"]}],"id":[{"id":"10.13039\/100001063","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004869","name":"Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Crohn's disease (CD) and ulcerative colitis (UC) have a chronic-remittent course. Optimal management of inflammatory bowel diseases (IBD) relies on early intervention, treat-to-target strategies and a tight disease control. However, it is challenging to assess the risk of relapses in individual patients. We investigated blood-based biomarkers for the confirmation of disease remission in patients with IBD. We retrospectively analyzed samples of 40 IBD patients (30 UC, 10 CD) enrolled in a tight-control follow-up study.\u00a0Half of the patients had a flare during follow up. Serum was analyzed for S100A12 as well as S100A8\/A9\u00a0and for 50 further biomarkers in a bead-based multiplex assay. The concentrations of 9 cytokines\/chemokines and S100A8\/A9 significantly differed in IBD patients with unstable remission (before flares) when compared to IBD patients with stable remission. Although the number of patients was small, ROC curve analyses revealed a number of biomarkers (IL-1\u03b2, IL-1RA, IL-8, IL13, IL-15, IL-21, IL-25, IFN-\u03b2, CXCL9, CXCL10, CXCL11, Galectin-1, G-CSF and S100A8\/A9) that were elevated in patients with later occurring relapses. While earlier studies on peripheral biomarkers in IBD are limited to only few analytes, our study using a broad screening approach identified serum biomarkers with the potential to indicate unstable disease control in IBD, which may help to steer individual therapies to maintain remission.<\/jats:p>","DOI":"10.1038\/s41598-021-86251-w","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T11:04:44Z","timestamp":1616497484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Serum biomarkers confirming stable remission in inflammatory bowel disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Christoph","family":"Kessel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miha","family":"Lavric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Weinhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Brueckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytze","family":"de Roock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00e4britz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"86251_CR1","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cgh.2013.09.006","volume":"13","author":"G Bouguen","year":"2015","unstructured":"Bouguen, G. et al. Treat to target: A proposed new paradigm for the management of Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 13, 1042-1050 e1042. https:\/\/doi.org\/10.1016\/j.cgh.2013.09.006 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"86251_CR2","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart, D. C. & Sandborn, W. J. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 369, 1641\u20131657. https:\/\/doi.org\/10.1016\/S0140-6736(07)60751-X (2007).","journal-title":"Lancet"},{"key":"86251_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ibd.21048","volume":"16","author":"CN Bernstein","year":"2010","unstructured":"Bernstein, C. N. et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm. Bowel Dis. 16, 112\u2013124. https:\/\/doi.org\/10.1002\/ibd.21048 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"86251_CR4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein, J. D. et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2020.01.006 (2020).","journal-title":"Gastroenterology"},{"key":"86251_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","volume":"114","author":"R Ungaro","year":"2019","unstructured":"Ungaro, R. et al. A treat-to-target update in ulcerative colitis: A systematic review. Am. J. Gastroenterol. 114, 874\u2013883. https:\/\/doi.org\/10.14309\/ajg.0000000000000183 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"86251_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/ecco-jcc\/jjz041","volume":"13","author":"RC Ungaro","year":"2019","unstructured":"Ungaro, R. C. et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J. Crohns Colitis 13, 963\u2013969. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz041 (2019).","journal-title":"J. Crohns Colitis"},{"key":"86251_CR7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet, L. et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am. J. Gastroenterol. 110, 1324\u20131338. https:\/\/doi.org\/10.1038\/ajg.2015.233 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"86251_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.giec.2014.03.005","volume":"24","author":"A Walsh","year":"2014","unstructured":"Walsh, A., Palmer, R. & Travis, S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest. Endosc. Clin. N. Am. 24, 367\u2013378. https:\/\/doi.org\/10.1016\/j.giec.2014.03.005 (2014).","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"86251_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22861","author":"R Mao","year":"2012","unstructured":"Mao, R. et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm. Bowel Dis. https:\/\/doi.org\/10.1002\/ibd.22861 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"86251_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/ecco-jcc\/jjy182","volume":"13","author":"E Louis","year":"2019","unstructured":"Louis, E. Do we still need predictors of disease severity when applying a treat-to-target approach in inflammatory bowel disease?. J. Crohns Colitis 13, 399\u2013400. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy182 (2019).","journal-title":"J. Crohns Colitis"},{"key":"86251_CR11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1053\/j.gastro.2019.06.018","volume":"157","author":"PS Dulai","year":"2019","unstructured":"Dulai, P. S. et al. Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases. Gastroenterology 157, 1032-1043 e1031. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.018 (2019).","journal-title":"Gastroenterology"},{"key":"86251_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser, C. et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohns Colitis 13, 144\u2013164. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy113 (2019).","journal-title":"J. Crohns Colitis"},{"key":"86251_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","volume":"13","author":"A Sturm","year":"2019","unstructured":"Sturm, A. et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J. Crohns Colitis 13, 273\u2013284. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy114 (2019).","journal-title":"J. Crohns Colitis"},{"key":"86251_CR14","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1093\/ibd\/izz078","volume":"25","author":"LA Denson","year":"2019","unstructured":"Denson, L. A. et al. Challenges in IBD research: Precision medicine. Inflamm. Bowel Dis. 25, S31\u2013S39. https:\/\/doi.org\/10.1093\/ibd\/izz078 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"86251_CR15","doi-asserted-by":"publisher","first-page":"e00138","DOI":"10.14309\/ctg.0000000000000138","volume":"11","author":"LY Mak","year":"2020","unstructured":"Mak, L. Y. et al. Combined use of common fecal and blood markers for detection of endoscopically active inflammatory bowel disease. Clin. Transl. Gastroenterol. 11, e00138. https:\/\/doi.org\/10.14309\/ctg.0000000000000138 (2020).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"86251_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00535-016-1191-3","volume":"51","author":"JO Musci","year":"2016","unstructured":"Musci, J. O., Cornish, J. S. & Dabritz, J. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J. Gastroenterol. 51, 531\u2013547. https:\/\/doi.org\/10.1007\/s00535-016-1191-3 (2016).","journal-title":"J. Gastroenterol."},{"key":"86251_CR17","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1016\/j.crohns.2013.06.008","volume":"7","author":"MA Meuwis","year":"2013","unstructured":"Meuwis, M. A. et al. Serum calprotectin as a biomarker for Crohn\u2019s disease. J. Crohns Colitis 7, e678\u2013e683. https:\/\/doi.org\/10.1016\/j.crohns.2013.06.008 (2013).","journal-title":"J. Crohns Colitis"},{"key":"86251_CR18","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2018","unstructured":"Colombel, J. F. et al. Effect of tight control management on Crohn\u2019s disease (CALM): A multicentre, randomised, controlled phase 3 trial. Lancet 390, 2779\u20132789. https:\/\/doi.org\/10.1016\/S0140-6736(17)32641-7 (2018).","journal-title":"Lancet"},{"key":"86251_CR19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/MIB.0000000000001140","volume":"23","author":"A Buisson","year":"2017","unstructured":"Buisson, A. et al. Comparative acceptability and perceived clinical utility of monitoring tools: A nationwide survey of patients with inflammatory bowel disease. Inflamm. Bowel Dis. 23, 1425\u20131433. https:\/\/doi.org\/10.1097\/MIB.0000000000001140 (2017).","journal-title":"Inflamm. Bowel Dis."},{"key":"86251_CR20","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1080\/00365521.2018.1527394","volume":"53","author":"R Kalla","year":"2018","unstructured":"Kalla, R. et al. Patients\u2019 perceptions of faecal calprotectin testing in inflammatory bowel disease: Results from a prospective multicentre patient-based survey. Scand. J. Gastroenterol. 53, 1437\u20131442. https:\/\/doi.org\/10.1080\/00365521.2018.1527394 (2018).","journal-title":"Scand. J. Gastroenterol."},{"key":"86251_CR21","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/ibd\/izz081","volume":"25","author":"BN Limketkai","year":"2019","unstructured":"Limketkai, B. N. et al. US practice patterns and impact of monitoring for mucosal inflammation after biologic initiation in inflammatory bowel disease. Inflamm. Bowel Dis. 25, 1828\u20131837. https:\/\/doi.org\/10.1093\/ibd\/izz081 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"86251_CR22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1097\/MIB.0000000000000139","volume":"20","author":"WK van Deen","year":"2014","unstructured":"van Deen, W. K. et al. A nationwide 2010\u20132012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm. Bowel Dis. 20, 1747\u20131753. https:\/\/doi.org\/10.1097\/MIB.0000000000000139 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"86251_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/2050640616686517","volume":"5","author":"C Marechal","year":"2017","unstructured":"Marechal, C. et al. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United Eur. Gastroenterol. J. 5, 702\u2013707. https:\/\/doi.org\/10.1177\/2050640616686517 (2017).","journal-title":"United Eur. Gastroenterol. J."},{"key":"86251_CR24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli, M. H. et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am. J. Gastroenterol. 110, 802\u2013819. https:\/\/doi.org\/10.1038\/ajg.2015.120 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"86251_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/MIB.0b013e318280b1cd","volume":"19","author":"J Dabritz","year":"2013","unstructured":"Dabritz, J. et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm. Bowel Dis. 19, 1130\u20131138. https:\/\/doi.org\/10.1097\/MIB.0b013e318280b1cd (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"86251_CR26","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/ajg.2013.360","volume":"108","author":"J Dabritz","year":"2013","unstructured":"Dabritz, J. et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am. J. Gastroenterol. 108, 1901\u20131910. https:\/\/doi.org\/10.1038\/ajg.2013.360 (2013).","journal-title":"Am. J. Gastroenterol."},{"key":"86251_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/gut.52.6.847","volume":"52","author":"D Foell","year":"2003","unstructured":"Foell, D. et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52, 847\u2013853. https:\/\/doi.org\/10.1136\/gut.52.6.847 (2003).","journal-title":"Gut"},{"key":"86251_CR28","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1136\/gut.2006.113431","volume":"56","author":"T Kaiser","year":"2007","unstructured":"Kaiser, T. et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56, 1706\u20131713. https:\/\/doi.org\/10.1136\/gut.2006.113431 (2007).","journal-title":"Gut"},{"key":"86251_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/ard.2006.061853","volume":"66","author":"W de Jager","year":"2007","unstructured":"de Jager, W. et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: A cross-sectional study. Ann. Rheum. Dis. 66, 589\u2013598. https:\/\/doi.org\/10.1136\/ard.2006.061853 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"86251_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jim.2005.03.009","volume":"300","author":"W de Jager","year":"2005","unstructured":"de Jager, W. et al. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods 300, 124\u2013135. https:\/\/doi.org\/10.1016\/j.jim.2005.03.009 (2005).","journal-title":"J. Immunol. Methods"},{"key":"86251_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CDLI.10.1.133-139.2003","volume":"10","author":"W de Jager","year":"2003","unstructured":"de Jager, W. et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 10, 133\u2013139 (2003).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"86251_CR32","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/annrheumdis-2013-204986","volume":"74","author":"K Hambardzumyan","year":"2015","unstructured":"Hambardzumyan, K. et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: Results from the SWEFOT trial. Ann. Rheum. Dis. 74, 1102\u20131109. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204986 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"86251_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3109\/00365521.2013.772230","volume":"48","author":"CG af Bjorkesten","year":"2013","unstructured":"af Bjorkesten, C. G. et al. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn\u2019s disease. Scand. J. Gastroenterol. 48, 543\u2013551. https:\/\/doi.org\/10.3109\/00365521.2013.772230 (2013).","journal-title":"Scand. J. Gastroenterol."},{"key":"86251_CR34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2019.10.034","volume":"158","author":"G D'Haens","year":"2020","unstructured":"D\u2019Haens, G. et al. Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins. Gastroenterology 158, 515-526 e510. https:\/\/doi.org\/10.1053\/j.gastro.2019.10.034 (2020).","journal-title":"Gastroenterology"},{"key":"86251_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa230","author":"R Kalla","year":"2020","unstructured":"Kalla, R. et al. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. J. Crohns Colitis https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa230 (2020).","journal-title":"J. Crohns Colitis"},{"key":"86251_CR36","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/ajg.2016.342","volume":"111","author":"R Kalla","year":"2016","unstructured":"Kalla, R. et al. Serum calprotectin: A novel diagnostic and prognostic marker in inflammatory bowel diseases. Am. J. Gastroenterol. 111, 1796\u20131805. https:\/\/doi.org\/10.1038\/ajg.2016.342 (2016).","journal-title":"Am. J. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86251-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:37:16Z","timestamp":1670045836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86251-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86251"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86251-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DF received research grants from Pfizer. JD received consultation fees, research grants, royalties, or honorarium from AbbVie, Shire\/Takeda, Humana, Nestl\u00e9, Ferring, Amgen, Nutricia and GlaxoSmithKline. JW is employee of B\u00dcHLMANN. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6690"}}